Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ: SRPT )

98.37 -1.40 (-1.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 736,577
Open 99.65
Bid (Size) 90.44 (1)
Ask (Size) 104.00 (1)
Prev. Close 99.77
Today's Range 97.11 - 100.00
52wk Range 97.91 - 173.25
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting. 
Via Benzinga
SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) showing high EPS and FCF growth while beating expectations
A fundamental analysis of (NASDAQ:SRPT): SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill

Performance

YTD
-20.73%
-20.73%
1 Month
-12.75%
-12.75%
3 Month
-21.55%
-21.55%
6 Month
-23.38%
-23.38%
1 Year
-19.37%
-19.37%

More News

Read More
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
8 Analysts Have This To Say About Sarepta Therapeutics
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
2 Growth Stocks to Buy Hand Over Fist in February
Via The Motley Fool
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics
Via Benzinga
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue
Via StockStory
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts
Via Benzinga
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Via MarketBeat
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
Via Benzinga
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
From Sarepta Therapeutics, Inc.
Via Business Wire
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
Via Benzinga
Exposures Product Safety
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
From Sarepta Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.